The Efficacy of HanShiYi Decoction for COVID 19 Patients: A Randomized, Controlled, Open-label Clinical trial
- Conditions
- Covid 19
- Registration Number
- ITMCTR2200005826
- Lead Sponsor
- The Affiliated Hospital to Changchun University of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
1. Patients should meet the diagnostic criteria for patients with COVID 19 in China's New Coronary Virus Pneumonia Diagnosis and Treatment Program (Trial Ninth Version);
2. The clinical classification is mild and common type;
3. The first nucleic acid positive time should not exceed 48 hours;
4. The patient's aged >=18 years old;
5. Sign the informed consent.
1. Patients meet the early warning indicators of severe/critical types;
2. Patients who have used similar proprietary Chinese medicines before enrollment;
3. Immunodeficiency diseases, or those who have used immunosuppressive agents or glucocorticoids within the past 3 months;
4. Women who are planning to become pregnant, pregnant women and lactating women;
5. Patients with allergies (referring to those allergic to more than two kinds of drugs or foods, or to the known ingredients of the drug in this trial);
6. Mental patients, or those without self-awareness;
7. Patients not suitable to participate in clinical trials.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method